Screener / SEC EDGAR /CIK 0001809987 /10-K filed Feb 19, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Technology · Measuring Instruments

Mirion Technologies, Inc. MIR

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 19, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+44.6%

The MD&A has no sentence that names a cause for this change.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

2.9% to 5.6% (+2.7 pts)

The MD&A has no sentence that names a cause for this change.

Gross margin

Change, FY to Dec 31, 2025 vs Dec 31, 2024

46.4% to 47.4% (+1.0 pts)

“Cost of revenues related to the Medical segment decreased $2.8 million period over period primarily due to favorable margins as a result of product mix in the current period, partially offset by inflationary impacts.”

Read it in the 10-K

“Cost of revenues related to the Medical segment increased $6.6 million period over period due to an increase in cost of revenues due to higher operations from organic growth over the same period, increased depreciation, increased costs from the ec2 acquisition, and inflation, partially offset by a reduction of cost of revenues from the disposal of Rehab (see Note 2, Business Combinations, Acquisitions, and Business Disposals, to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K) and various cost productivity initiatives.”

Read it in the 10-K

Revenue

Change, FY to Dec 31, 2025 vs Dec 31, 2024

+7.5%

“Nuclear & Safety segment revenues increased $53.5 million for the year ended December 31, 2025 compared with the year ended December 31, 2024 primarily due to current period acquisitions, foreign exchange fluctuations, organic volume growth, and price increases.”

Read it in the 10-K

“Medical segment revenues increased $11.1 million for the year ended December 31, 2025 compared with the year ended December 31, 2024 primarily due to price increases, recovery from operational delays in the comparable prior period, foreign exchange fluctuations, and organic volume growth.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +7.5%

    “Nuclear & Safety segment revenues increased $53.5 million for the year ended December 31, 2025 compared with the year ended December 31, 2024 primarily due to current period acquisitions, foreign exchange fluctuations, organic volume growth, and price increases.”

    Read it in the FY 2025 10-K

    “Medical segment revenues increased $11.1 million for the year ended December 31, 2025 compared with the year ended December 31, 2024 primarily due to price increases, recovery from operational delays in the comparable prior period, foreign exchange fluctuations, and organic volume growth.”

    Read it in the FY 2025 10-K
  • FY 2024 +7.5%

    “Revenues increased $15.6 million due to price increases, $41.0 million from volume growth, and $11.4 million due to the acquisition of the ec2 business.”

    Read it in the FY 2024 10-K

    “Medical segment revenues increased $15.2 million for the year ended December 31, 2024 compared with the year ended December 31, 2023 primarily due to price increases, organic volume growth, and the current year impact of the ec2 acquisition.”

    Read it in the FY 2024 10-K

Gross margin

2 of 2 years explained
  • FY 2025 +1.0 pts

    “Cost of revenues related to the Medical segment decreased $2.8 million period over period primarily due to favorable margins as a result of product mix in the current period, partially offset by inflationary impacts.”

    Read it in the FY 2025 10-K

    “Cost of revenues related to the Medical segment increased $6.6 million period over period due to an increase in cost of revenues due to higher operations from organic growth over the same period, increased depreciation, increased costs from the ec2 acquisition, and inflation, partially offset by a reduction of cost of revenues from the disposal of Rehab (see Note 2, Business Combinations, Acquisitions, and Business Disposals, to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K) and various cost productivity initiatives.”

    Read it in the FY 2025 10-K
  • FY 2024 +1.9 pts

    “Cost of revenues related to the Medical segment increased $6.6 million period over period due to an increase in cost of revenues due to higher operations from organic growth over the same period, increased depreciation, increased costs from the ec2 acquisition, and inflation, partially offset by a reduction of cost of revenues from the disposal of Rehab (see Note 2, Business Combinations, Acquisitions, and Business Disposals, to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K) and various cost productivity initiatives.”

    Read it in the FY 2024 10-K

    “Cost of revenues related to the Medical segment decreased $3.3 million period over period due to a reduction of cost of revenues from the disposal of Rehab (see Note 3, Disposal of a Business, to the Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K) and an improvement in product margin mix.”

    Read it in the FY 2024 10-K

Operating margin

0 of 2 years explained
  • FY 2025 +2.7 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +5.6 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Cash from operations

0 of 2 years explained
  • FY 2025 +44.6%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +4.1%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MIR/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.